Raltitrexed increases tumorigenesis as a single agent yet exhibits anti-tumor synergy with 5-fluorouracil in ApcMin/+ mice

Cancer Biology and Therapy

Volumn 3, Issue 11, 2004, Pages 1169-1176

  Murphy, John T ^a   Tucker, Jody M ^a   Davis, Celestia ^a   Berger, Franklin G ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

5 fluorouracil; Apcmin + mouse; Raltitrexed; Synergy; Tumorigenesis

Indexed keywords

BROXURIDINE; FLUOROURACIL; RALTITREXED; ANTINEOPLASTIC AGENT; APC PROTEIN; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADENOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL MOTILITY; CONTROLLED STUDY; DOSE RESPONSE; EXPERIMENTAL MODEL; FEMALE; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; INTESTINE CANCER; INTESTINE CRYPT; INTESTINE EPITHELIUM CELL; MALE; MONOTHERAPY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CYTOLOGY; DRUG POTENTIATION; EPITHELIUM CELL; GENETICS; INTESTINE TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADENOMA; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; EPITHELIAL CELLS; FEMALE; FLUOROURACIL; INTESTINAL NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, INBRED C57BL; QUINAZOLINES; THIOPHENES; TUMOR BURDEN;

EID: 22144473011     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.11.1220     Document Type: Article

References (51)

1. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995; 64:721-62.
2. McGuire JJ. Anticancer antifolates: Current status and future directions. Curr Pharm Des 2003; 9:2593-613.
3. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51:5579-80.
4. Berger SH, Hakala MT. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 1984; 25:303-9.
5. Wright JE, Dreyfuss A, el-Magharbel I, Trites D, Jones SM, Holden SA, Rosowsky A, Frei E 3rd. Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 1989; 49:2592-6.
6. Mansoni S. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345:939-44.
7. Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson RW, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10:896-903.
8. Caradonna SJ, Cheng YC. The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells. Mol Pharmacol 1980; 18:513-20.
9. Schuetz JD, Wallace HJ, Diasio RB. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res 1984; 44:1358-63.
10. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-8.
11. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989; 63:1026-30.
12. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407-18..
13. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16:2943-52.
14. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Ann Oncol 1996; 7:961-5.
15. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998; 77:15-21.
16. Jackman AL, Kimbell R, Ford HE. Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations. Eur J Cancer 1999; 35:S3-8.
17. Caponigro F, Avallone A, McLeod H, Carteni G, De Vita F, Casaretti R, Morsman J, Blackie R, Budillon A, De Lucia L, Gravina A, Catalano G, Comella P, Comella G. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. Clin Cancer Res 1999; 5:3948-55.
18. Comella P, De Vita F, Mancarella S, De Lucia L, Biglietto M, Casaretti R, Farris A, Ianniello GP, Lorusso V, Avallone A, Carteni G, Leo SS, Catalano G, De Lena M, Comella G. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Ann Oncol 2000; 11:1323-33.
19. Schwartz GK, Bertino J, Kemeny N, Saltz L, Kelsen DK, Tong W, Welch M, Endres S, Dimery I. Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. Anticancer Drugs 2004; 15:219-27.
20. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247:322-4.
21. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992; 256:668-70.
22. Levy DB, Smith KJ, Beazer-Barclay Y, Hamilton SR, Vogelstein B, Kinzler KW. Inactivation of both APC alleles in human and mouse tumors. Cancer Res 1994; 54:5953-8.
23. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-70.
24. Shoemaker AR, Gould KA, Luongo C, Moser AR, Dove WF. Studies of neoplasia in the Min mouse. Biochim Biophys Acta 1997; 1332:F25-48.
25. Min/+ mice. Cancer Lett 2002; 187:153-62.
26. Raghunathan K, Schmitz JC, Priest DG. Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice. Biochem Pharmacol 1997; 53:1197-202.
27. Moolenbeek C, Ruitenberg EJ. The "Swiss roll": A simple technique for histological studies of the rodent intestine. Lab Anim 1981; 15:57-9.
28. Min/+ mice. Cancer Res 2002; 62:6367-70.
29. Luongo C, Moser AR, Gledhill S, Dove WF. Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res 1994; 54:5947-52.
30. Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying atruncated Apc gene. Proc Natl Acad Sci USA 1995; 92:4482-6.
31. Shoemaker AR, Moser AR, Dove WF. N-ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: Age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. Cancer Res 1995; 55:4479-85.
32. Paulsen JE, Steffensen IL, Namork E, Eide TJ, Alexander J. Age-dependent susceptibility to azoxymethane-induced and spontaneous tumorigenesis in the Min/+ mouse. Anticancer Res 2003; 23:259-65.
33. Steffensen IL, Paulsen JE, Eide TJ, Alexander J. 2-Amino-1-methyl-6- phenylimidazo[4,5-b]pyridine increases the numbers of tumors, cystic crypts and aberrant crypt foci in multiple intestinal neoplasia mice. Carcinogenesis 1997; 18:1049-54.
34. Potten CS. Stem cells in gastrointestinal epithelium: Numbers, characteristics and death. Philos Trans R Soc Lond B Biol Sci 1998; 353:821-30.
35. Krokan HE, Standal R, Slupphaug G. DNA glycosylases in the base excision repair of DNA. Biochem J 1997; 325:1-16.
36. Mahmoud NN, Boolbol SK, Bilinski RT, Martucci C, Chadburn A, Bertagnolli MM. Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Res 1997; 57:5045-50.
37. Min/+ mice. Carcinogenesis 2003; 24:1219-24.
38. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61:5193-201.
39. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, Boland CR. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117:123-31.
40. Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, Daniel R, Skalka AM, Meropol NJ, Alberti C, Larue L, Bellacosa A. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci USA 2003; 100:15071-6.
41. Sansom OJ, Zabkiewicz J, Bishop SM, Guy J, Bird A, Clarke AR. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 2003; 22:7130-6.
42. Sahasrabudhe PV, Pon RT, Gmeiner WH. Solution structures of 5-fluorouracil-substituted DNA and RNA decamer duplexes. Biochemistry 1996; 35:13597-608.
43. Hardeland U, Bentele M, Lettieri T, Steinacher R, Jiricny J, Schar P. Thymine DNA glycosylase. Prog Nucleic Acid Res Mol Biol 2001; 68:235-53.
44. Hardeland U, Bentele M, Jiricny J, Schar P. The versatile thymine DNA-glycosylase: A comparative characterization of the human, Drosophila and fission yeast orthologs. Nucleic Acids Res 2003; 31:2261-71.
45. Krokan HE, Drablos F, Slupphaug G. Uracil in DNA - occurrence, consequences and repair. Oncogene 2002; 21:8935-48.
46. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22:9063-74.
47. Longo GS, Izzo J, Chang YM, Tong WP, Zielinski Z, Gorlick R, Chou TC, Bertino JR. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. Clin Cancer Res 1998; 4:469-73. .
48. Yan JM, Lu ZH, Shao LN, Diasio RB, et al. The effect of 'Tomudex' on dihydropyrimidine dehydrogenase activity. Proc Am Assoc Cancer Res 1997:4133, Abstract.
49. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13:1663-70.
50. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98:610-5.
51. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53:5433-8.